GlassScriptPhysician profile
Alexander Muniz
NPI 1073234597
$1,741.39
in general payments reported to CMS, 2019-2025
19 companies · $783 in 2025
The $783 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $79.40 · 2023: $314 · 2024: $565 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,572.99 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $283.22 | 2023-2025 | |
| Stryker Corporation | $257.91 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Artix Mt |
| Amgen INC. | $216.21 | 2022-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $146.51 | 2022-2025 | Uptravi, Opsumit |
| Inari Medical, INC. | $140.70 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Merck Sharp & Dohme LLC | $134.21 | 2022-2025 | Verquvo |
| Boston Scientific Corporation | $122.41 | 2023-2025 | Watchman Access System, Cds - Mct/Cem Monitoring |
| Scpharmaceuticals INC. | $71.94 | 2024-2025 | |
| Pfizer INC. | $61.74 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $55.53 | 2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $39.04 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $35.21 | 2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $34.32 | 2024 | Onpattro |
| Medtronic, INC. | $29.09 | 2023 | Linq II |
| Heartflow, INC. | $27.21 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.31 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $24.23 | 2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.58 | 2024 | Lifevest |
| Glaxosmithkline, LLC. | $14.02 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Muniz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.